$79.32
-0.87-1.08%
In chiusura: Nov 20, 4:00 PM EST
$78.18
-1.14-1.44%
Post-mercato: Nov 20, 7:54 PM EST

DexCom (DXCM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
| Trimestre fiscale | Data segnalata | EPS effettivo | EPS stimato | Sorpresa% |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $0.73 | $0.67 | 8.96 % |
| Q2 | Jul 30, 2026 | $0.70 | $0.61 | 14.8 % |
| Q1 | Apr 30, 2026 | $0.56 | $0.47 | 19.1 % |
| Q4 | Feb 12, 2026 | $0.68 | $0.65 | 4.62 % |
Quarterly Revenue (Billions)
| Trimestre fiscale | Data segnalata | Entrate effettive | Entrate stimate | Sorpresa% |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $1.34B | $1.33B | 1.40 % |
| Q2 | Jul 30, 2026 | $1.31B | $1.29B | 1.25 % |
| Q1 | Apr 30, 2026 | $1.19B | $1.18B | 1.29 % |
| Q4 | Feb 12, 2026 | $1.26B | $1.25B | 0.61 % |
DexCom (DXCM) ha pubblicato l'ultima guidance il ottobre 29, 2026 per fiscal year 2026. La società ha previsto un fatturato pari a $5.2B - $5.25B per il periodo.
Rispetto alle previsioni precedenti, DexCom ha modificato le sue previsioni di fatturato da un intervallo precedente di .
DexCom ha pubblicato {{revenueDirection}} aggiornamenti delle previsioni tra il {{revenuePriorRange}} e il DexCom. 29
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.67 | $0.61 | $0.47 | $0.65 |
| Actual | $0.73 | $0.70 | $0.56 | $0.68 |
| Surprise | +8.96% | +14.8% | +19.1% | +4.62% |
| Revenue | ||||
| Estimate | $1.33B | $1.29B | $1.18B | $1.25B |
| Actual | $1.34B | $1.31B | $1.19B | $1.26B |
| Surprise | +1.40% | +1.25% | +1.29% | +0.61% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.72 | $0.63 | $0.76 | $0.81 |
| Revenue | ||||
| Consensus | $1.39B | $1.31B | — | — |